Enoxaparin Sodium Injection; Rivaroxaban Tablets — Competitive Intelligence Brief

Enoxaparin Sodium Injection; Rivaroxaban Tablets (Enoxaparin Sodium Injection; Rivaroxaban Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

phase 2 Anticoagulant Factor Xa, Factor IIa Cardiovascular Small molecule

Target snapshot

Enoxaparin Sodium Injection; Rivaroxaban Tablets (Enoxaparin Sodium Injection; Rivaroxaban Tablets) — Beijing Suncadia Pharmaceuticals Co., Ltd. Enoxaparin sodium injection works by inhibiting Factor Xa and Factor IIa, preventing blood clot formation, while rivaroxaban tablets inhibit Factor Xa directly.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Enoxaparin Sodium Injection; Rivaroxaban Tablets TARGET	Enoxaparin Sodium Injection; Rivaroxaban Tablets	Beijing Suncadia Pharmaceuticals Co., Ltd	phase 2	Anticoagulant	Factor Xa, Factor IIa
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
enoxaparin + clopidogrel + aspirin	enoxaparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Factor Xa, Factor IIa, P2Y12 receptor, cyclooxygenase
Enoxaparin followed by VKA	Enoxaparin followed by VKA	Bayer	phase 3	Anticoagulant (low-molecular-weight heparin bridged to vitamin K antagonist)	Factor Xa, Factor IIa (enoxaparin); Vitamin K-dependent clotting factors II, VII, IX, X (VKA)
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

1. Fresenius Kabi · 4 drugs in this class
2. University of Sao Paulo · 3 drugs in this class
3. Beijing Anzhen Hospital · 2 drugs in this class
4. San Filippo Neri General Hospital · 2 drugs in this class
5. Yong Seog Oh · 2 drugs in this class
6. CCRF Consulting Co., Ltd. · 1 drug in this class
7. Boston Scientific Corporation · 1 drug in this class
8. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
9. Faculty Hospital Kralovske Vinohrady · 1 drug in this class
10. Deutsches Herzzentrum Muenchen · 1 drug in this class